Local innovative pharmaceutical companies are ready to innovate and constantly break the monopoly of multinational pharmaceutical companies!

【Pharmaceutical Network Industry News】For a long time, many domestic drugs have been occupied by multinational pharmaceutical companies in the market share
.
In recent years, national policies to encourage pharmaceutical innovation, such as volume procurement and medical insurance negotiation, have gradually advanced, in this context, local innovative drugs aim at the unmet clinical demand prospects of domestic patients, increase R&D investment, accumulate innovation, focus on the research and development of more new drugs, and constantly break the monopoly of multinational pharmaceutical companies, bringing good news
to patients.
For example, Benaglutide, a GLP-1 receptor agonist for diabetes treatment independently developed by Renhui Biologics, was first prescribed
in February 2017.
Previously, GLP-1 receptor agonists in the domestic market were almost monopolized by multinational pharmaceutical giants such as Novo Nordisk, AstraZeneca, and Eli Lilly, and after the listing of beniruttide, it means that the monopoly of
multinational pharmaceutical companies has been broken.
Domestic new drugs are also supported
by medical insurance policies.
On December 28, 2020, Renhui Biologics' benirutide injection was included in the new version of the national medical insurance catalogue, which brought greater good news to diabetics in China and helped improve the accessibility of
drugs.
In addition to targeting the field of diabetes treatment, Renhui Biotech also plans to launch a new obesity drug BEM-014 (a new indication for benanalutide in the field of weight loss)
in 2023.
In March 2022, the marketing application for BEM-014 (a new indication for benalutide in the field of weight loss) was accepted, and if successfully approved, it will become the first original new drug
for weight loss in China.
It is reported that BEM-014 has also received support
from the "National 'Thirteenth Five-Year' Major New Drug Creation Project" and Shanghai's 2019 "Science and Technology Innovation Action Plan" industry-university-research-medical cooperation project during the research and development process.
China is a country with a relatively large number of obese people in the world, more than 50% of adults are overweight/obese, and overweight/obesity is easy to cause intercurrent diseases, affecting patients' physical health and quality of life
.
It is reported that studies have found that a small weight loss can improve these comorbidities, weight loss of 5% ~ 15%, 10% is appropriate, can greatly reduce the occurrence of complications and improve the quality of life
.
At present, the domestic demand for drug treatment for overweight/obesity is far from being met
.
The original drug has been delisted in the market, and only generic orlistat drugs have been approved for use, so there is a market space
for pharmaceutical companies to tap.
For example, in 2012, Novartis' ranibizumab for the treatment of wet age-related macular degeneration entered China, monopolized the Chinese market at a price of 9800 yuan per unit, injected once a month, and the annual treatment cost was nearly 120,000 yuan, bringing a heavy burden
to patients and patients' families.
In the context of accelerated review and approval, the domestic new drug Combocept was launched in 2013 with a listing price of 6800 yuan, breaking Novartis' monopoly and reducing the burden
of patient costs.
In the case of welcoming competitors, Novartis also made a price adjustment, taking the initiative to reduce the price by 2600 yuan / unit
.
At the same time, medical insurance negotiations have further forced pharmaceutical companies to reduce prices and reduce the burden
on patients.
In 2017, when Combocept first conducted medical insurance negotiations, it was reduced by 17%, and the price was 5550 yuan per unit; In 2019, the second medical insurance negotiation decreased by 25% to 4160 yuan per unit; In the third medical insurance negotiation in 2021, the price will be reduced by 17% to 3450 yuan / unit
.
According to the proportion of 50%~70% reimbursement of medical insurance in various places, calculated with a low reimbursement of 50%, using a combocept, patients only need to pay 1150 yuan at their own expense, inject once in 3 months, and the monthly treatment fee is about 400 yuan, and the patient's drug burden has been greatly reduced
.
Conclusion Behind the continuous breaking of the monopoly of multinational pharmaceutical companies by domestic innovative drugs, the innovation ability of China's pharmaceutical enterprises is being further enhanced
.
Data show that 47 innovative drugs were reviewed and passed in 2021, hitting a record high
.
As innovative drug companies continue to make efforts, it is expected to usher in more local innovative drugs in the future, which will benefit the majority of patients
.